Background: Recently the feasibility of combining carboplatin with paclitaxel has been demonstrated in dose-finding studies. Maximum tolerated doses were 550 mg/m 2 and 200 mg/m
Introduction
Carboplatin (cis-diammine 1,1-cyclobutane dicarboxylate platinum (II), CBDCA, JM8, NCS-241240, Paraplatin®) is a second-generation platinum-containing chemotherapeutic compound, with established activity against a variety of solid tumors [1] [2] [3] . Its dose-limiting toxicity is myelosuppression, predominantly thrombocytopenia. Carboplatin is much less nephrotoxic, neurotoxic and emetogenic than its parent compound cisplatin [1, 2] . A two-drug combination of either cisplatin or carboplatin plus the alkylating agent cyclophosphamide has, until recently, been the treatment of choice for stage III and IV ovarian cancer [2] . However, despite high objective response rates, durable remissions are uncommon and relapses occur frequently.
A major step forward after the introduction of the platinum compounds was the demonstration of the activity of paclitaxel in ovarian carcinoma. Paclitaxel (NCS-125973, Taxol®) is a plant-derived anticancer agent, which promotes the assembly and stabilizes intracellular microtubules [4, 5] . Its dose-limiting toxicities are myelosuppression, particularly neutropenia, and neurotoxicity. Paclitaxel has shown activity in a variety of solid tumors, especially ovarian carcinoma [4, 6] . A recently completed phase III study has indicated that a combination of paclitaxel and cisplatin yields better response rates and survival than the cisplatin /cyclophosphamide combination [7] . Although survival analysis awaits maturation of the data, the paclitaxel/cisplatin combination may already be considered the standard treatment for ovarian carcinoma [8] . This combination is, however, associated with significant toxicity. Severe peripheral neuropathy and myalgias may occur and can be dose-limiting [9] . Since carboplatin has a relatively mild toxicity profile and has proven to substitute effectively for cisplatin, the combination of paclitaxel with carboplatin seemed a further logical step. A recently closed phase I trial in ovarian cancer patients performed in our institute yielded a maximum-tolerated dose (MTD) of 200 mg/m 2 paclitaxel, administered by a three-hour infusion, followed by 550 mg/m 2 carboplatin, as a 30-minute infusion, repeated every three weeks [10] . This treatment modality was well tolerated and yielded several responses. An administration-sequence dependent effect, as was observed for the cisplatin/paclitaxel combination, was not observed. We subsequently undertook a phase II study to investigate further the efficacy and toxicity of this combination in previously untreated patients with stage III or IV ovarian cancer.
Patients and methods

Patient selection
The patients had optimally or suboptimally debulked FIGO stage III or IV ovarian carcinoma, and had not received prior chemotherapy. Eligibility criteria included a WHO-performance status $2, life expectancy > 8 weeks, adequate bone marrow function (absolute neutrophil count (ANQ >2.0 x 10 9 /l and platelets 5= 100 x 10 9 /l), serum bihrubin $25 um, ALATand ASAT $2.5 x the normal upper limit, serum creatinine $110 um, age < 70 years, adequate cardiac function with no history of arrhythmias, and no pre-existing motor or sensory neurotoxicity ^ grade I (WHO-criteria). The protocol was approved by the Medical Ethical Committee of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital in Amsterdam, and informed consent was obtained from all patients.
Treatment plan
Carboplatin (Paraplatin®; Bristol-Myers Squibb, Syracuse, NY) was supplied as lyophilized product containing 150 mg carboplatin and 150 mg manmtol as bulking agent. Immediately before use the content of each vial was reconstituted with 15 ml of Water for Injection, and the total dose was added to 250 ml dextrose 5%. Paclitaxel (Taxol®; Bristol-Myers Squibb, Syracuse, NY) was supplied as concentrated sterile solution (6 mg/ml) in a 5-ml vial in polyoxyethylated castor oil (Cremophor EL®) and dehydrated alcohol (1:1 vol/vol). These were diluted before use with 0.9% sodium chloride to achieve a total volume of about 1000 ml. Paclitaxel (200 mg/nr) was administered as a threehour infusion immediately followed by a 30-minute infusion of carboplatin (550 mg/irT). Standard premedication consisted of dexamethason (20 mg orally, 12 and 6 hours prior to paclitaxel infusion), clemastine (2 mg i.v.), and cimetidine (300 mg l.v.), and granisetron for antiemetic prophylaxis. Courses were repeated at 21-day intervals, provided that the ANC count was greater than 1.5 x 10 9 /l, the platelet count was greater than 100 x 10 9 /l. If on day 21 the ANC and platelet counts had not recovered, the next cycle of therapy was delayed a week, up to a maximum of three weeks. In that case, the patient was taken off treatment.
Response criteria
The duration of therapy was six cycles in the absence of disease progression. Assessment of antitumor response was made after every two courses by complete physical and gynaecological examination, chest X-ray, CT-scan or by ultrasound as required measurable tumor locations. Patients who had normalization of serum CA-125 levels with complete disappearance of all measurable disease for at least four weeks were considered to have a clinical complete remission (cCR). Partial remission (PR) was defined as a > 50% decrease in the sum of the products of the diameters of measurable lesions for at least four weeks. Simultaneous increase in the size of any lesion, or appearance of any new lesion was not allowed to occur. Stable disease (SD) was defined as a less than 25% increase and a less than 50% decrease in tumor size, for at least eight weeks. Progressive disease (PD) was defined as an increase in tumor size of >25%, or the appearance of a new lesion. In patients with PD treatment was immediately discontinued. Intervention debulking was allowed in patients with gross tumor mass after initially obtaining adequate tumor regression (i.e., PR). Second-look surgery was recommended for all optimally debulked patients and patients in clinical complete remission If patients were macroscopically free of disease but with visable tumor cells in blind peritoneal biopsies or with cytologically positive peritoneal lavage they were considered to have minimal residual disease (MRD), patients without any evidence of disease had a pathologically confirmed CR (pCR).
Statistical considerations
The primary end point of this study was to assess the feasibility of administering the two-drug combination at a three week interval to patients with suboptimally debulked ovarian cancer. A secondary objective was to gain a preliminary estimate of the activity of the regimen. Patients who had received any protocol therapy were considered assessable for toxicity, which was graded according WHO-cntena. All patients receiving at least one course of therapy were considered assessable for response. The progression free interval was defined as the time between the start of therapy to the first sign of progression.
Results
Between March 1995 and February 1996, a total of 21 ovarian cancer patients were enrolled into this phase II study. The mean age was 56 (range 34 to 72) years, and the median performance status was 1 (range 0 to 2). Ten patients had FIGO stage IV, and 11 patients had FIGO stage III. Most patients (n = 15) had suboptimally debulked disease at the start of therapy. Most patients received six courses of therapy (median: 6, range: 4 to 9). Overall, a total of 131 courses were administered, of which 32 courses (24.4%) were postponed one week because of unrecovered neutropenia.
All patients were evaluable for toxicity. Myelosuppression was the predominant toxicity. In all patients the main hematological toxicity during the first course was neutropenia with 38% of the courses resulting in grade III neutropenia, and 48% resulting in grade IV neutropenia (Table 1 ). Only 15% of the patients experienced grade III or IV thrombocytopenia during the first course. The most severe degree of toxicity experienced by each patient across all cycles for each category is presented in Table 2 . Overall, the majority of patients (18 out of 21) experienced grade IV neutropenia during 67% of the courses. This was complicated by neutropenic fever (38^0 °C) in only 12% (16 out of 131 courses). Serious infections or sepsis did not occur. Furthermore, 42% of all courses resulted in grade III thrombocytopenia, and only 19% in grade IV. This toxicity was equally distributed over all patients, since eventually most patients experienced one or more episodes of grade III or IV thrombocytopenia (Table 2) . Cumulative toxicity was not observed. Mild anemia (grade II) occurred in 57% of the patients, and grade III in 28%. (10) 3 (14) 3 (14) 0 1(5) 12 (57) 6 (28) 1 (5) 3 (14) 6 (28) 9 (42) 2 (10) 3(14) 0 3 (14) 18 (84) 12(57) Note. WHO-toxicity grades are used.
Most patients complained of paresthesias, or dysesthesias in hands or feet, yielding grade I neurotoxicity in 85% of the patients. Myalgia and bone pain appeared in one half of the patients, and was generally mild. Nausea and vomiting of mild to moderate severity was experienced by the majority of patients, but could easily be controlled by standard antiemetic medication. Other gastrointestinal toxicities (anorexia, mucositis, diarrhea) of mild to moderate severity occurred in a minority of patients. All patients developed alopecia (grade II or III). Fatigue was a common side-effect of the treatment, and was severe (grade III) in four patients.
Antitumor activity
Most patients {n = 20) were assessable for response evaluation. Fifteen patients had measurable lesions, and six patients had optimally debulked disease (all lesions < 1 cm) when entering the study (Table 3) . One optimally debulked patient was not evaluated laparoscopically and was consequently considered not evaluable for response. For the suboptimally debulked patients (« = 15) the combination of paclitaxel and carboplatin was highly active: all patients responded to therapy. Five out of seven patients with PR underwent intervention debulking, the other patients had a cCR. Eventually, seven patients underwent second-look surgery, and this revealed in five patients a pCR. The median follow-up interval at the time of analysis was 14 months (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Three patients died of progressive disease after 8, 11, and 14 months, respectively. Six patients have progressive disease, yielding a progression free interval of respectively 5, 8, 10, 11, 11, and 13 months. The other 12 patients have no evidence of disease.
Discussion
Most is progressively accepted that the standard chemotherapeutic treatment for stage II or IV ovarian cancer is the combination paclitaxel with cisplatin. This regimen has shown to yield higher response rates and better survival as compared to other platinum-based regimens [7, 8] . This combination has, however, significant toxicity and alternatives should be pursued. Carboplatin has a favourable toxicity profile over cisplatin, and has proven to be equivalent to the treatment with cisplatin 15(100) 7(100) [2] . We therefore performed a phase I trial for the combination carboplatin/paclitaxel, which yielded a well tolerated, active regimen, with dosages higher than used in single-agent regimens [10] . This phase II trial was initiated to confirm it activity and establish further the toxicity. Neutropenia grade IV was the principal toxicity, with thrombocytopenia and mild anemia occurring regularly. The lack of thrombocytopenia as observed in the phase I study [10] , where most courses were repeated at a 28-day interval, could be confirmed. Only 19% of the courses resulted in grade IV thrombocytopenia, and 42% of the courses in grade III thrombocytopenia, while generally at a dosage of 400 mg/m 2 carboplatin thrombocytopenia would be dose-limiting. This was also observed in a phase II study with carboplatin and paclitaxel administered to patients with non-small-cell lung cancer at three weeks intervals, where at a carboplatin dosage of 434 mg/m 2 only 9% of the courses induced thrombocytopenia [11] . Also other studies with the paclitaxelcarboplatin combination reported only minimal thrombocytopenia at conventional doses [12] [13] [14] [15] , and even at higher dosages [16, 17] . Furthermore, no treatment delays occurred due to unrecovered thrombocytopenia, although a 21-day treatment interval was applied. These findings suggests that there is a considerable interaction of both drugs at the cellular level, yielding a protective effect of paclitaxel on the carboplatin toxicity (thrombocytopenia). The underlying mechanism explaining the protective properties of paclitaxel is not clear. In a study of Obasaju et al. patients were randomized to receive carboplatin alone or immediately followed by paclitaxel to address this question. A pharmacokinetic explanation was considered unlikely, since carboplatin clearances were equal for both treatment groups. Other explanations were not found.
In conclusion, the combination of paclitaxel (200 mg/m 2 ) and carboplatin (550 mg/m 2 ) every three weeks is well-tolerated and is feasible for outpatient treatment. Both drugs can be given safely in combination at more than full doses. Reduced platelet toxicity in combination with pronounced neutropenia are the main toxicities of this combination. Comparative, prospective trials to evaluate its activity versus the cisplatin/ paclitaxel combination are currently in progress.
